Reviva Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RVPH) $3.84 0.00 (0.00%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$3.78▼$3.9950-Day Range$3.71▼$6.0452-Week Range$3.03▼$9.25Volume229,605 shsAverage Volume428,003 shsMarket Capitalization$86.86 millionP/E RatioN/ADividend YieldN/APrice Target$16.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Reviva Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside336.8% Upside$16.75 Price TargetShort InterestBearish14.61% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.17Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.51) to ($1.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.83 out of 5 starsMedical Sector716th out of 949 stocksPharmaceutical Preparations Industry338th out of 442 stocks 3.5 Analyst's Opinion Consensus RatingReviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.75, Reviva Pharmaceuticals has a forecasted upside of 336.8% from its current price of $3.84.Amount of Analyst CoverageReviva Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.61% of the outstanding shares of Reviva Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverReviva Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Reviva Pharmaceuticals has recently increased by 30.83%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldReviva Pharmaceuticals does not currently pay a dividend.Dividend GrowthReviva Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RVPH. Previous Next 1.0 News and Social Media Coverage News SentimentReviva Pharmaceuticals has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Reviva Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 10 people have searched for RVPH on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders31.83% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 24.09% of the stock of Reviva Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($1.51) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reviva Pharmaceuticals is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reviva Pharmaceuticals is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.Read More RVPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVPH Stock News HeadlinesNovember 30, 2023 | finance.yahoo.comReviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor ConferenceNovember 27, 2023 | msn.comReviva Pharmaceuticals Holdings (RVPH) Price Target Increased by 13.48% to 17.17December 1, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 24, 2023 | americanbankingnews.comZacks Small Cap Comments on Reviva Pharmaceuticals Holdings, Inc.'s FY2023 Earnings (NASDAQ:RVPH)November 21, 2023 | finanznachrichten.deReviva Pharmaceuticals: Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNovember 20, 2023 | finance.yahoo.comReviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNovember 20, 2023 | finance.yahoo.comRVPH: Raise & RECOVER Results ReviewNovember 16, 2023 | finance.yahoo.comReviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesDecember 1, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 16, 2023 | finance.yahoo.comReviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNovember 15, 2023 | finanznachrichten.deReviva Pharmaceuticals: Reviva Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNovember 14, 2023 | finance.yahoo.comReviva Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNovember 14, 2023 | finance.yahoo.comReviva Pharmaceuticals Holdings Inc Reports Q3 2023 Financial ResultsNovember 2, 2023 | msn.comReviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It StartedNovember 1, 2023 | morningstar.comReviva Pharmaceuticals Holdings Inc Ordinary SharesNovember 1, 2023 | finance.yahoo.comRVPH: RECOVER ToplineOctober 31, 2023 | msn.comHC Wainwright & Co. Maintains Reviva Pharmaceuticals Holdings (RVPH) Buy RecommendationOctober 31, 2023 | msn.comRoth MKM Reiterates Reviva Pharmaceuticals Holdings (RVPH) Buy RecommendationOctober 30, 2023 | reuters.comREVIVA PHARMACEUTICALS, INC.October 30, 2023 | benzinga.comCould This Be A Breakthrough in Mental Health? Reviva's Schizophrenia Drug Shows Promising Results In Key TrialOctober 30, 2023 | msn.comReviva posts late-stage data for schizophrenia candidateOctober 30, 2023 | marketwatch.comReviva Pharma Sees Positive Results in Trial for Schizophrenia TreatmentOctober 30, 2023 | reuters.comReviva Pharma's schizophrenia drug succeeds in late-stage studyOctober 13, 2023 | bizjournals.comSchizophrenia drug developer eyes late-stage clinical trial data this monthSeptember 29, 2023 | finanznachrichten.deSharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report on Bloomberg TVSeptember 29, 2023 | finance.yahoo.comSharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TVSeptember 27, 2023 | msn.comReviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVERSee More Headlines Receive RVPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVPH CUSIPN/A CIK1742927 Webwww.revivapharma.com Phone(408) 501-8881FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$16.75 High Stock Price Target$20.00 Low Stock Price Target$12.00 Potential Upside/Downside+335.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,344.46% Return on Assets-307.04% Debt Debt-to-Equity RatioN/A Current Ratio0.41 Quick Ratio0.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.38) per share Price / Book-10.13Miscellaneous Outstanding Shares22,650,000Free Float15,441,000Market Cap$87.20 million OptionableNot Optionable Beta0.04 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Laxminarayan Bhat Ph.D. (Age 58)Founder, CEO, President & Director Comp: $560kMr. Narayan Prabhu (Age 51)Chief Financial Officer Comp: $412.5kKey CompetitorsG1 TherapeuticsNASDAQ:GTHXOramed PharmaceuticalsNASDAQ:ORMPCytomX TherapeuticsNASDAQ:CTMXWerewolf TherapeuticsNASDAQ:HOWLMediciNovaNASDAQ:MNOVView All CompetitorsInstitutional OwnershipGTS Securities LLCBought 12,100 shares on 11/16/2023Ownership: 0.000%Armistice Capital LLCSold 224,000 shares on 11/15/2023Ownership: 2.649%GSA Capital Partners LLPBought 51,270 shares on 11/15/2023Ownership: 0.310%Sabby Management LLCBought 1,124 shares on 11/15/2023Ownership: 0.000%Silverarc Capital Management LLCBought 564,000 shares on 11/13/2023Ownership: 0.000%View All Institutional Transactions RVPH Stock Analysis - Frequently Asked Questions Should I buy or sell Reviva Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RVPH shares. View RVPH analyst ratings or view top-rated stocks. What is Reviva Pharmaceuticals' stock price target for 2024? 4 brokerages have issued 1 year target prices for Reviva Pharmaceuticals' stock. Their RVPH share price targets range from $12.00 to $20.00. On average, they expect the company's stock price to reach $16.75 in the next year. This suggests a possible upside of 336.8% from the stock's current price. View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts. How have RVPH shares performed in 2023? Reviva Pharmaceuticals' stock was trading at $4.25 at the beginning of the year. Since then, RVPH shares have decreased by 9.8% and is now trading at $3.8350. View the best growth stocks for 2023 here. Are investors shorting Reviva Pharmaceuticals? Reviva Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 3,310,000 shares, an increase of 30.8% from the October 31st total of 2,530,000 shares. Based on an average daily volume of 1,100,000 shares, the short-interest ratio is presently 3.0 days. View Reviva Pharmaceuticals' Short Interest. When is Reviva Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our RVPH earnings forecast. How were Reviva Pharmaceuticals' earnings last quarter? Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.11. Who are Reviva Pharmaceuticals' major shareholders? Reviva Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (2.65%), Silverarc Capital Management LLC (0.00%), Group One Trading L.P. (0.00%), EMC Capital Management (0.55%), Belvedere Trading LLC (0.00%) and GSA Capital Partners LLP (0.31%). Insiders that own company stock include Prabhu Narayan, Purav Patel and Vedanta Partners, Llc. View institutional ownership trends. How do I buy shares of Reviva Pharmaceuticals? Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:RVPH) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.